Stockreport

Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome

Azitra Inc  (AZTR) 
PDF BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a precision dermatology company, announced that it has initiated dosing the first patient in it [Read more]